SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing market pressure after its CagriSema obesity drug did not achieve non-inferiority against Eli Lilly's competitor in a recent trial, fueling community debate over its competitive standing. However, strong early demand for its oral Wegovy, coupled with recent regulatory actions against compounded GLP-1 alternatives and ongoing share buybacks, is leading many to see the current sell-off as an overreaction and a potential buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection extending to 2044 for bipolar I disorder and schizophrenia. Community sentiment is largely bullish on significant upside potential and a possible short squeeze, though some express caution regarding a recent shelf offering and the drug's similarity to an existing therapy.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Recent positive clinical data for Arcellx's multiple myeloma CAR-T therapy, anito-cel, showcases strong efficacy and a differentiated safety profile, driving current conversation. An expanded strategic partnership and investment from Kite (Gilead), combined with the recent lifting of a partial clinical hold, reinforces market confidence and highlights the company's competitive edge in the cell therapy landscape.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Dominos Pizza is drawing attention after its Q4 earnings report showcased solid results and strategic investments, further amplified by Berkshire Hathaway's increased stake. The community is actively debating if its focus on value and digital initiatives can continue to drive market share in a competitive restaurant environment.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting stellar Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, demonstrating high efficacy and potential disease-modifying effects. This positive data, coupled with a major institutional investor significantly increasing its stake and an anticipated Investor Day, has ignited strong community discussion about its "best-in-class" potential, a potential re-rating, and a short squeeze.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as the community processes its solid Q4 earnings beat against conservative 2026 guidance, alongside significant M&A activity including the Arcellx acquisition and key patent settlements for its dominant HIV franchise. Investors are also closely watching developments in its oncology pipeline, such as recent Trodelvy trial results, amid discussions about the company's long-term growth trajectory in a volatile market.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its Mainnet recently went live and a partnership with Aplix for a Japan-regulated stablecoin was announced, alongside its inclusion in Coinbase's institutional index for perpetual futures. This has sparked a polarized community discussion, with proponents highlighting these fundamental advancements for long-term potential, while critics remain skeptical given the token's continued price performance.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's latest obesity drug trial underperformed Eli Lilly's, reigniting community discussion that Viking's competitive dual agonist VK2735 is now a highly attractive acquisition or partnership target for pharmaceutical giants eager to capture market share.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community debate intensifies around recent tariff rulings and new global levies, with widespread discussion focusing on their economic impact and concerns over the company's financial stability and potential dilution ahead of upcoming disclosures.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals is trending after securing a significant patent victory for its Nuplazid drug, ensuring market exclusivity and prompting multiple analyst upgrades. The community is actively discussing the company's robust, potentially undervalued pipeline in neurological and rare diseases, balancing this against recent EU regulatory challenges for its Rett syndrome treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Minerva Neurosciences (NERV) to Release Earnings on Tuesday

Minerva Neurosciences (NASDAQ:NERV) will be releasing its Q4 2025 earnings before the market opens on Tuesday, February 24. (View Earnings Report at...

Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update

Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest...

Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia

Minerva Neurosciences (NASDAQ:NERV) hosted a virtual key opinion leader (KOL) event focused on its development candidate roluperidone for negative symptoms in schizophrenia, outlining the clinical...

Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Above 50 Day Moving Average - What's Next?

Minerva Neurosciences (NASDAQ:NERV) Stock Price Crosses Above 50 Day Moving Average - Here's What Happened...

Minerva Neurosciences (NASDAQ:NERV) Cut to Sell at Wall Street Zen

Wall Street Zen cut Minerva Neurosciences from a "hold" rating to a "sell" rating in a report on Sunday...

Minerva Neurosciences (NASDAQ:NERV) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised Minerva Neurosciences from a "sell" rating to a "hold" rating in a research note on Saturday...

<ul class="summary-bullets"><li>Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.</li><li>The FDA cleared the design for a confirmatory Phase 3 trial of roluperidone, a potential treatment for the negative symptoms of schizophrenia.</li><li>Retail traders on Stocktwits turned “extremely bullish,” citing the new funding and FDA alignment as signs of confidence in an eventual approval.</li></ul>Minerva Neurosciences' stock jumped to a nearly two-year high on Tuesday after the biotech firm announced a new financing deal that could bring in up to $200 million and outlined a clear regulatory path with the U.S. FDA for its lead schizophrenia drug, roluperidone.The company’s shares&nbsp;soared 141% to $6.41 on Tuesday, hitting their highest level since February 2024, before slipping 6.4% in after-hours trading.<h2 class="st-heading-2">Funding For Phase 3 Trial And NDA Resubmission</h2>Minerva said it raised $80 million upfront through a private financing round backed by leading healthcare investors, including Vivo Capital, Janus Henderson Investors, and Federated Hermes Kaufmann Funds.&nbsp;The deal could bring in as much as $200 million in total, with another $80 million tied to the exercise of Tranche A warrants and an additional $40 million linked to future clinical milestones under Tranche B warrants. Each preferred share was priced at $1,000, convertible into common stock at $2.11 pending shareholder approval.The firm said the investment would fully fund its planned confirmatory Phase 3 study of roluperidone, and NDA resubmission to the FDA. It will also be used to make preparations for a potential U.S. commercial launch, should the product gain approval.<h2 class="st-heading-2">Strengthening The Team</h2>Under the agreement, Minerva will increase the number of its directors to include up to three new members with significant experience in schizophrenia and drug development. The company also plans to establish a Scientific Advisory Board to help guide the Phase 3 study.“We will now refocus all of our efforts on the successful execution of the confirmatory trial with the objective of demonstrating that roluperidone can effectively treat patients with impairing negative symptoms,” CEO Remy Luthringer said in a statement.<h2 class="st-heading-2">FDA Agrees On Clear Trial Design</h2>The FDA has agreed on the design of the confirmatory Phase 3 study, which will test roluperidone 64 mg as a standalone treatment in patients with schizophrenia who suffer from negative symptoms such as lack of motivation, social withdrawal, and diminished emotional expression. The main goal of the trial will be to measure improvements in the PANSS Marder Negative Symptoms Factor Score after 12 weeks.The FDA has also asked Minerva to observe patients for up to 52 weeks to monitor relapse rates, helping to build evidence for roluperidone as a monotherapy. The company expects around 25%–30% of trial participants to be enrolled from U.S. sites.<h2 class="st-heading-2">Stocktwits Traders Eye FDA Milestone Upside</h2>On Stocktwits, retail sentiment for Minerva was ‘extremely bullish’ amid a 102,300% surge in 24-hour message volume.One user said they expected Minerva’s stock to climb sharply if it breaks past the $7 level, while another pointed to the company’s $200 million financing as a sign of confidence, suggesting that such investment likely reflects optimism around eventual FDA approval.<stembedurl>https://stocktwits.com/24cmKarMadhfromPrishtina/message/633140308</stembedurl><stembedurl>https://stocktwits.com/Myway1000/message/633126607</stembedurl><a href="https://stocktwits.com/symbol/NERV">Minerva’s stock</a> has nearly tripled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Minerva Neurosciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst

Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.

Equity

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

NERV
Minerva Neurosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NERV News

NERVMinerva Neurosciences Inc